期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021
卷 61, 期 -, 页码 779-803出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-050120-105018
关键词
senescence; senolytics; senomorphics; senescence-associated secretory phenotype; aging
资金
- National Institutes of Health [P01 AG062412, P01 AG043376, R01 AG063543, R56 AG059676, R56 AG059675, U19 AG056278, R33 AG062018, R01 AG068048, R37 AG 013925, R01 AG069048, UL1 TR0002377]
- Medical Discovery Team Biology of Aging
- Robert and Arlene Kogod Center on Aging
- Connor Group
- Ted Nash Long Life Foundation
- Noaber Foundation
- BBSRC [BB/K017314/1] Funding Source: UKRI
Senescence is a signaling mechanism activated in stressed cells to prevent proliferation of damaged cells, leading to chronic sterile inflammation and age-related diseases. Senescent cells accumulate with age and in diseased anatomical sites, making them a logical therapeutic target. Senotherapeutics, a new class of drugs, selectively kill senescent cells or suppress their disease-causing phenotypes, showing promising results in preclinical studies and clinical trials.
Senescence is the consequence of a signaling mechanism activated in stressed cells to prevent proliferation of cells with damage. Senescent cells (Sncs) often develop a senescence-associated secretory phenotype to prompt immune clearance, which drives chronic sterile inflammation and plays a causal role in aging and age-related diseases. Sncs accumulate with age and at anatomical sites of disease. Thus, they are regarded as a logical therapeutic target. Senotherapeutics are a new class of drugs that selectively kill Sncs (senolytics) or suppress their disease-causing phenotypes (senomorphics/senostatics). Since 2015, several senolytics went from identification to clinical trial. Preclinical data indicate that senolytics alleviate disease in numerous organs, improve physical function and resilience, and suppress all causes of mortality, even if administered to the aged. Here, we review the evidence that Sncs drive aging and disease, the approaches to identify and optimize senotherapeutics, and the current status of preclinical and clinical testing of senolytics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据